Detection of circulating tumor cells in breast cancer patients: prognostic predictive role (original) (raw)
Related papers
Circulating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
Journal of Clinical Oncology, 2009
Purpose Five or more circulating tumor cells (CTCs) per 7.5 mL of blood predicts for poorer progression-free survival (PFS) in patients with metastatic breast cancer (MBC). We conducted a prospective study to demonstrate that CTC results correlate strongly with radiographic disease progression at the time of and in advance of imaging. Patients and Methods Serial CTC levels were obtained in patients starting a new treatment regimen for progressive, radiographically measurable MBC. Peripheral blood was collected for CTC enumeration at baseline and at 3- to 4-week intervals. Clinical outcomes were based on radiographic studies performed in 9- to 12-week intervals. Results Sixty-eight patients were evaluable for the CTC-imaging correlations, and 74 patients were evaluable for the PFS analysis. Median follow-up was 13.3 months. A statistically significant correlation was demonstrated between CTC levels and radiographic disease progression in patients receiving chemotherapy or endocrine t...
Role of Circulating Tumor Cells in Determining Prognosis in Metastatic Breast Cancer
South Asian Journal of Cancer
Background Circulating tumor cells (CTCs) in the peripheral blood may play a major role in the metastatic spread of breast cancer. This study was conducted to assess the role of CTCs to determine the prognosis in terms of survival in metastatic breast cancer patients. Methods This prospective study of 36 patients was conducted at the Hospital from April 2016 to May 2018. Details of each patient related to the demographic profile, tumor type, treatment, and follow-up information were recorded. The number of CTCs in the peripheral blood was measured by Celsee PREP 400 sample processing system and Celsee Analyzer imaging station. Results There was a positive correlation between the number of site of metastasis with number of CTCs (p-value < 0.001). In the patients with clinical/partial response, a significant reduction in the number of CTCs after 1 month of therapy was observed (p-value = 0.003). When the number of CTCs at baseline and 6 months were compared with the positron emissi...
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Clinical cancer research : an official journal of the American Association for Cancer Research, 2016
Although unequivocal evidence has shown the prognostic relevance of circulating tumor cells (CTCs) in the peripheral blood of patients with metastatic breast cancer, less evidence is available for the prognostic relevance of CTCs at the time of primary diagnosis. We conducted a pooled analysis of individual data from 3,173 patients with non-metastatic (Stage I-III) breast cancer from 5 breast cancer institutions. The prevalence and numbers of CTCs were assessed at the time of primary diagnosis with the United States Food and Drug Administration-cleared CellSearch® System (Janssen Diagnostics, LLC). Patient outcomes were analyzed using meta-analytic procedures, univariate log-rank tests, and multivariate Cox proportional hazard regression analyses. The median follow-up duration was 62.8 months. One or more CTCs were detected in 20.2% of the patients. CTC-positive patients had larger tumors, increased lymph node involvement, and a higher histological tumor grade than did CTC-negative ...
Breast Cancer Research, 2011
Introduction Circulating tumor cells (CTCs) represent an independent predictor of outcome in patients with metastatic breast cancer (MBC). We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients. Methods We retrospectively evaluated 235 newly diagnosed MBC patients, treated at the University of Texas MD Anderson Cancer Center. All patients had a baseline CTC assessment performed with CellSearch®. Progression-free survival and overall survival were compared with the log-rank test between groups, according to CTC count (< 5 vs. ≥ 5) and type of systemic therapy. We further explored the predictive value of baseline CTCs in patients receiving different treatments. Results At a median follow-up of 18 months, the CTC count was confirmed to be a robust prognostic marker in the overall population (median progression-free survival 12.0 and 7.0 months for patients with CTC < 5 and ≥ 5, respectively; P < 0.001). Conversely, in patients with human epidermal growth factor receptor-2-overexpressed/amplified tumors receiving trastuzumab or lapatinib, the baseline CTC count was not prognostic (median progression-free survival 14.5 months for patients with CTC < 5 and 16.1 months for those with CTC ≥ 5; P = 0.947). Furthermore, in patients with human epidermal growth factor receptor-2 normal tumors, a baseline CTC count ≥ 5 identified subjects who derived benefit from more aggressive treatments, including combination chemotherapy and chemotherapy plus bevacizumab. Conclusions This analysis suggests that the prognostic information provided by CTC count may be useful in patient stratifications and therapeutic selection, particularly in the group with positive CTCs, in which various therapeutic choices may procure differential palliative benefit.
Cancer Research, 2009
#303 Background: The detection of Disseminated Tumor Cells in the Bone Marrow (BM) of Breast Cancer patients has shown prognostic significance in all stages of the disease. An alternative towards BM examination could be the analysis of peripheral blood for Circulating Tumor Cells (CTCs), which has demonstrated prognostic significance in metastatic disease. We analyzed peripheral blood samples from pts. Before and after adjuvant taxane-based chemotherapy as part of the translational research program of the German SUCCESS-trial. Methods: Peripheral blood samples (23 ml each) from 1500 N+ and high risk N- breast cancer pts were analyzed for the presence of CTCs with the CellSearchSystem (Veridex, USA) before and after adjuvant chemotherapy. After automated immunomagnetic enrichment with an anti-Epcam-antibody, cells are labelled with anti-cytokeratin (8,18,19) and anti-CD45 antibodies to distinguish between epithelial cells and leukocytes. Samples are screened automatedly and positiv...